Histamine H₂ receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H₂ receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen ions in exchange for potassium ions, culminating in gastric acid production.

H₂ receptor antagonists are pivotal players in regulating gastric acid levels. These antagonists compete with histamine for H₂ receptors, obstructing histamine binding and suppressing gastric acid production. Beyond this primary function, these antagonists also curb the direct stimulation of parietal cells by acetylcholine or gastrin, further reducing acid production in response to these stimuli.

Four distinct H₂ receptor antagonists — cimetidine, ranitidine, famotidine, and nizatidine — have proven their efficacy in this arena. These blockers are administered during sleep and exhibit acid-suppressing capabilities, aiding ulcer healing.

These drugs are metabolized by the liver and are cleared from the body through the kidneys. Due to this metabolic pathway, lower doses are advisable for geriatric patients or individuals with compromised renal function. By effectively inhibiting histamine's influence on H₂ receptors, these antagonists serve as valuable tools in managing gastric acid secretion, promoting healing, and improving the overall gastrointestinal health of individuals affected by conditions such as ulcers.